All In Biotech

NDA 022288 · Bausch and Lomb INC

Bepreve

Bepotastine Besilate · Ophthalmic

Novel

Last checked: Nov 19, 2026Latest source record: Feb 9, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Sep 8, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

25

7 Phase 3, 0 recruiting

FAERS reports

644

361 serious, 38 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 20, 2024.

Bepotastine Besilate Ophthalmic Solution, 1.5% is a histamine H 1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. Bepotastine Besilate Ophthalmic Solution is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis. ( 1 )

Mechanism: Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BEPREVE · BEPOTASTINE BESILATE 1.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Bepotastine Besilate" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective45
  • headache36
  • nausea33
  • eye irritation32
  • fatigue32
  • pain29
  • diarrhoea28
  • pruritus27
  • treatment failure26
  • dyspnoea25
  • off label use25
  • asthma24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20083
20092
201022
201146
201211
201318
201417
201545
201647
201773
201862
201976
202065
202154
202222
202325
202422
202523
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bepreve (Bepotastine Besilate)

2024 spending

$1.5M

Beneficiaries

1,193

3,553 claims

Per beneficiary

$1,257

$54.52 per unit

View as table
YearSpending
2020$18,279,728
2021$18,335,829
2022$11,213,463
2023$3,010,497
2024$1,499,995

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.